These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8028755)

  • 1. [The effects of the carbocalcitonin + arginine-lysine-lactose combination in senile involutional osteoporosis].
    Abate G; Taormina F; Brillante C; Fraccalaglio L
    Minerva Med; 1994 May; 85(5):253-9. PubMed ID: 8028755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Experience regarding the use of arginine-lysine-lactose treatment in menopausal osteoporosis].
    Bellati U; Liberati M
    Minerva Med; 1994 Jun; 85(6):327-32. PubMed ID: 8084436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Sequential calcitriol-calcitonin in the therapy of osteoporosis].
    Passeri M; Palummeri E; Barbagallo M; Butturini L; Pedrazzoni M; Davoli L; Pioli G; Benassi L; Girasole G; Ciotti G
    Minerva Endocrinol; 1989; 14(1):57-62. PubMed ID: 2659953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Experimental osteoporosis caused by estrogen deficiency in rats. Role of a lactose, L-arginine and L-lysine combination in the prevention and therapy].
    Fini M; Giardino R; Mongiorgi R; Cantelli Forti G; Gnudi S; Nicoli Aldini N; Valdrè C; Piotti D; Giavaresi G; Orienti L; Rocca M; Sapone A; Rossetti A
    Minerva Med; 1996 Mar; 87(3):81-8. PubMed ID: 8668292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative analysis of therapeutic effects of carbocalcitonin and and conjugated estrogens in post-menopausal osteoporosis].
    Surico N; Tavassoli K
    Minerva Ginecol; 1990 Dec; 42(12):529-37. PubMed ID: 2089296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
    Malavolta N; Zanardi M; Veronesi M; Ripamonti C; Gnudi S
    Int J Tissue React; 1999; 21(2):51-9. PubMed ID: 10568224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A; Barone A; Pioli G; Girasole G; Siccardi V; Palummeri E; Bianchi G
    Nephrol Dial Transplant; 2009 May; 24(5):1472-7. PubMed ID: 19075192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of lactose, arginine and lysine combination in fracture healing (an experimental study)].
    Fini M; Giardino R; Nicoli Aldini N; Martini L; Rocca M; Bertoni F; Capelli S; Cantelli Forti G; Sapone A; Rossetti A; Morrone G; Giavaresi G
    Ann Ital Chir; 1996; 67(1):77-82; discussion 82-3. PubMed ID: 8712622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E; Puglisi N; Mamazza C; Lo Giudice F; Testai M; Abbate S; Santangelo A; Panebianco P; Maugeri D
    Eur Rev Med Pharmacol Sci; 2004; 8(2):97-102. PubMed ID: 15267123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The use of parenteral clodronate in elderly women with postmenopausal osteoporosis: compliance, effects on bone mineral density and on bone turnover].
    Celi M; Balducci S; Schiappoli A; Caliumi C; Petramala L; Cerci S; Cotesta D; D'Erasmo E; Letizia C
    Ann Ital Med Int; 2003; 18(2):89-98. PubMed ID: 12886826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].
    Brodowska A
    Ann Acad Med Stetin; 2003; 49():111-30. PubMed ID: 15552843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in bone mineral density and selected metabolic parameters over 24 months following renal transplantation.
    Al-Gabri S; Zadrazil J; Krejcí K; Horák P; Bachleda P
    Transplant Proc; 2005 Mar; 37(2):1014-9. PubMed ID: 15848609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supplementation of L-arginine prevents glucocorticoid-induced reduction of bone growth and bone turnover abnormalities in a growing rat model.
    Pennisi P; D'Alcamo MA; Leonetti C; Clementi A; Cutuli VM; Riccobene S; Parisi N; Fiore CE
    J Bone Miner Metab; 2005; 23(2):134-9. PubMed ID: 15750691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis.
    Brixen KT; Christensen PM; Ejersted C; Langdahl BL
    Basic Clin Pharmacol Toxicol; 2004 Jun; 94(6):260-70. PubMed ID: 15228497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 3-year pilot study with 1,25-dihydroxyvitamin D, calcium, and calcitonin for severe osteodystrophy in primary biliary cirrhosis.
    Floreani A; Zappala F; Fries W; Naccarato R; Plebani M; D'Angelo A; Chiaramonte M
    J Clin Gastroenterol; 1997 Jun; 24(4):239-44. PubMed ID: 9252849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Behavior of urinary excretion of cyclic AMP in post-menopausal osteoporosis during therapy with salmon calcitonin].
    Nuti R; Galli M; Righi GA; Turchetti V; Campagna MS; Franci B
    Minerva Med; 1982 May; 73(19):1283-9. PubMed ID: 6281691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis.
    Hodsman AB; Fraher LJ; Ostbye T; Adachi JD; Steer BM
    J Clin Invest; 1993 Mar; 91(3):1138-48. PubMed ID: 8450043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Randomized comparative study using carbocalcitonin i.m. vs carbocalcitonin nasal spray vs ipriflavone x os in the treatment of post-menopausal osteoporosis].
    Lobianco R; Merola B; Lupoli G; Cocca A; Guarino M; Pia M; Guerriero S; Lombardi G
    Minerva Endocrinol; 1992; 17(2):79-84. PubMed ID: 1296148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of different "coherent"-type therapeutic plans on bone mineral density and on the incidence of vertebral fractures in advanced osteoporosis].
    Cristallini S; Pedetti M; Donatelli C; Gregorio F; Filipponi P
    Recenti Prog Med; 1993 May; 84(5):336-45. PubMed ID: 8390084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.